Research indicates that compromised BMPR-II signaling in endothelial cells is a critical factor in the development of PAH. BMP9 and BMP10 have been identified as key circulating ligands that activate BMPR-II receptor complexes on these cells. Studies have shown that exogenous administration of BMP9 has the potential to enhance BMPR-II signaling and reverse PAH in rodent models.
MORPHOGEN-IX Limited aims to harness the potential of BMP9 and BMP10 for the treatment of PAH. Operating on a semi-virtual model with a hub in Cambridge, UK, the company has brought together PAH and BMP experts, along with seasoned drug discovery professionals. The latest investment of £18.40M in the Series B - Morphogen came on 18 December 2018, with contributions from Cambridge Innovation Capital, Medicxi, and University of Cambridge Enterprise. This funding is expected to drive the company's outsourced development program, ensuring capital efficiency and high-quality standards.
